var data={"title":"Chagas disease: Chronic Trypanosoma cruzi infection","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Chagas disease: Chronic Trypanosoma cruzi infection</div><dl id=\"topicContributors\"><dt><span> </span>Author:</dt><dd><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/contributors\" class=\"contributor contributor_credentials\">Caryn Bern, MD, MPH</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/contributors\" class=\"contributor contributor_credentials\">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/contributors\" class=\"contributor contributor_credentials\">Elinor L Baron, MD, DTMH</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Oct 25, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H707610184\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chagas disease is caused by infection with the protozoan parasite <em>Trypanosoma cruzi</em>; the major manifestations are Chagas cardiomyopathy and gastrointestinal disease [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/1\" class=\"abstract_t\">1</a>].</p><p>Issues related to the natural history, clinical manifestations, diagnosis, and management of chronic Chagas disease will be reviewed here. Issues related to acute and congenital Chagas infection are discussed separately. (See <a href=\"topic.htm?path=chagas-disease-acute-and-congenital-trypanosoma-cruzi-infection\" class=\"medical medical_review\">&quot;Chagas disease: Acute and congenital Trypanosoma cruzi infection&quot;</a>.)</p><p>Issues related to the epidemiology and prevention of Chagas disease are discussed separately. (See <a href=\"topic.htm?path=chagas-disease-epidemiology-and-prevention\" class=\"medical medical_review\">&quot;Chagas disease: Epidemiology and prevention&quot;</a>.)</p><p>Issues related to cardiac and gastrointestinal Chagas are discussed separately. (See <a href=\"topic.htm?path=chagas-heart-disease-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Chagas heart disease: Clinical manifestations and diagnosis&quot;</a> and <a href=\"topic.htm?path=chagas-heart-disease-treatment-and-prognosis\" class=\"medical medical_review\">&quot;Chagas heart disease: Treatment and prognosis&quot;</a> and <a href=\"topic.htm?path=chagas-gastrointestinal-disease\" class=\"medical medical_review\">&quot;Chagas gastrointestinal disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H481275196\"><span class=\"h1\">NATURAL HISTORY</span></p><p class=\"headingAnchor\" id=\"H2906167089\"><span class=\"h2\">Overview</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span><em>T. cruzi</em> infection is characterized by two phases, acute and chronic (<a href=\"image.htm?imageKey=ID%2F114565\" class=\"graphic graphic_figure graphicRef114565 \">figure 1</a>). The acute phase lasts 8 to 12 weeks after transmission. (See <a href=\"topic.htm?path=chagas-disease-acute-and-congenital-trypanosoma-cruzi-infection\" class=\"medical medical_review\">&quot;Chagas disease: Acute and congenital Trypanosoma cruzi infection&quot;</a>.)</p><p>When the host immune response succeeds in decreasing parasite replication, parasitemia falls below levels detectable by microscopy, acute symptoms resolve, and the patient passes into the chronic phase. In the absence of successful antitrypanosomal therapy, this usually occurs 8 to 12 weeks after the onset of infection, and the chronic phase lasts for the life of the patient. Nearly all <em>T. cruzi&ndash;</em>infected persons have the indeterminate (asymptomatic) form during the first one to three decades of the chronic phase; an estimated 20 to 30 percent will subsequently develop cardiac <span class=\"nowrap\">and/or</span> gastrointestinal forms of the disease [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/2\" class=\"abstract_t\">2</a>].</p><p>Individuals with chronic <em>T. cruzi</em> infection are capable of transmitting the parasite to the insect vector and to other humans via blood components, organ donation, or transplacentally, regardless of clinical manifestations [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"topic.htm?path=chagas-disease-epidemiology-and-prevention#H591899160\" class=\"medical medical_review\">&quot;Chagas disease: Epidemiology and prevention&quot;, section on 'Transmission'</a>.)</p><p class=\"headingAnchor\" id=\"H771514762\"><span class=\"h2\">Indeterminate form</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Patients with the indeterminate form of the chronic phase of <em>T. cruzi</em> infection have positive serology but no signs or symptoms of cardiomyopathy or gastrointestinal disease. Such patients have normal 12-lead electrocardiogram findings and normal radiographic examinations of the chest, esophagus, and colon [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/3,4\" class=\"abstract_t\">3,4</a>].</p><p>Parasympathetic autonomic dysfunction (including decreased respiratory heart rate changes and blunted heart rate responses to orthostatic changes) may be detected on specific testing in infected individuals with no signs of cardiomyopathy or digestive Chagas disease [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/5\" class=\"abstract_t\">5</a>]. One study including 511 <em>T. cruzi</em>&ndash;infected individuals noted presence of subclinical peripheral neuropathy (manifested as decreased tendon reflexes <span class=\"nowrap\">and/or</span> sensory impairment) in 10 percent of cases; there was no reported association with cardiomyopathy or gastrointestinal Chagas disease [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/6\" class=\"abstract_t\">6</a>]. About 20 to 30 percent of individuals with the indeterminate form of Chagas disease progress over a period of years to decades to clinically evident disease.</p><p class=\"headingAnchor\" id=\"H2096355592\"><span class=\"h2\">Determinate forms</span></p><p class=\"headingAnchor\" id=\"H960078338\"><span class=\"h3\">Heart disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chagas heart disease develops more commonly than gastrointestinal disease. Issues related to Chagas heart disease are discussed in detail separately. (See <a href=\"topic.htm?path=chagas-heart-disease-treatment-and-prognosis#H372251508\" class=\"medical medical_review\">&quot;Chagas heart disease: Treatment and prognosis&quot;, section on 'Management'</a>.)</p><p class=\"headingAnchor\" id=\"H1975704446\"><span class=\"h3\">Gastrointestinal disease</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The gastrointestinal form of Chagas disease is rare, especially outside of the Southern Cone countries (Bolivia, Argentina, Paraguay, Uruguay, Chile, Brazil). Issues related to Chagas gastrointestinal disease are discussed in detail separately. (See <a href=\"topic.htm?path=chagas-gastrointestinal-disease\" class=\"medical medical_review\">&quot;Chagas gastrointestinal disease&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3679823478\"><span class=\"h2\">Reactivation due to immunosuppression</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Reactivation of chronic <em>T. cruzi</em> infection can occur in patients with immunosuppression due to malignancy, chemotherapy, immunosuppressive regimens for solid organ or bone marrow transplantation, or <span class=\"nowrap\">HIV/AIDS</span> [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/7,8\" class=\"abstract_t\">7,8</a>]. Clinical findings and management are discussed in detail separately. (See <a href=\"topic.htm?path=chagas-disease-in-the-immunosuppressed-host\" class=\"medical medical_review\">&quot;Chagas disease in the immunosuppressed host&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H1462222214\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Chronic Chagas disease should be suspected in individuals who have lived in endemic countries of Latin America and those born to women from endemic countries. Most infected individuals are asymptomatic; cardiac or gastrointestinal symptoms in a patient from Latin America should prompt consideration of chronic Chagas disease.</p><p>Groups at highest risk include those who lived in rural areas, especially in houses with adobe walls, thatched roofs, <span class=\"nowrap\">and/or</span> known triatomine infestation. Vector-borne transmission also occurs in the southern United States, but the risk is much lower than in areas of Latin America with domestic triatomine infestation. Infection prevalence is highest in Bolivia, Argentina, Paraguay, and Ecuador, but most infected immigrants in the United States are from El Salvador and Mexico. (See <a href=\"topic.htm?path=chagas-disease-epidemiology-and-prevention\" class=\"medical medical_review\">&quot;Chagas disease: Epidemiology and prevention&quot;</a>.)</p><p class=\"headingAnchor\" id=\"H3676202985\"><span class=\"h2\">Laboratory testing</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Diagnosis of chronic Chagas infection requires serological methods to detect immunoglobulin (Ig)G antibodies to <em>T. cruzi</em>, most commonly enzyme-linked immunosorbent assay (ELISA) and immunofluorescent antibody assay (IFA) [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/1\" class=\"abstract_t\">1</a>]. No available assay has sufficient sensitivity and specificity to be used alone; a positive result by a single assay does not constitute a confirmed diagnosis [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/9\" class=\"abstract_t\">9</a>]. Two serological tests based on different antigens (eg, whole-parasite lysate and recombinant antigens) <span class=\"nowrap\">and/or</span> techniques (eg, ELISA and IFA) are used in parallel to increase the accuracy of the diagnosis [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/1,3\" class=\"abstract_t\">1,3</a>]. Data suggest that the sensitivity of serological assays varies by geographical location, possibly due to <em>T. cruzi</em> strain differences and resulting antibody responses [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/10-12\" class=\"abstract_t\">10-12</a>].</p><p>Individuals tested by two serological assays with discordant results require further testing. In some cases, the infection status remains difficult to resolve even after a third test because there is no true gold-standard assay for chronic <em>T. cruzi </em>infection [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/13\" class=\"abstract_t\">13</a>]. Assays such as the radioimmune precipitation assay (RIPA) and IgG trypomastigote excreted-secreted antigen immunoblot (IgG TESA-blot) are promoted as reference tests, but even these do not have optimal sensitivity and specificity and may not be capable of resolving the diagnosis [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/14,15\" class=\"abstract_t\">14,15</a>].</p><p>Options for <em>T. cruzi</em> serological testing in the United States are relatively limited. Three ELISA kits based on parasite lysate or recombinant antigens (Ortho ELISA, Wiener Chagatest ELISA Recombinante 3.0, Hemagen ELISA) are cleared by the US Food and Drug Administration (FDA) for diagnostic application [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/16\" class=\"abstract_t\">16</a>]. Of these three tests, the Ortho and Wiener ELISAs demonstrated high sensitivity and specificity in published evaluations [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/17,18\" class=\"abstract_t\">17,18</a>]. A rapid test based on recombinant antigens (InBios ChagasDetectPlus) was also cleared by the FDA and could facilitate screening of high-risk populations [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/19,20\" class=\"abstract_t\">19,20</a>]. Use of an assay with validation data (eg, a commercial kit shown to have acceptable sensitivity and specificity in a thorough study) is preferable to reliance on in-house tests for which no performance data are publicly available.</p><p>In general, polymerase chain reaction (PCR) is not a useful diagnostic test for chronic <em>T. cruzi</em> infection. The sensitivity is variable and depends on patient characteristics, sample volume, and PCR primers and methods [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/21,22\" class=\"abstract_t\">21,22</a>]. However, quantitative PCR performed under rigorously standardized protocols is increasingly used as a timely indicator of treatment failure in new drug trials. (See <a href=\"#H2413657394\" class=\"local\">'Assessing response to treatment'</a> below.)</p><p>Direct demonstration of parasite by hemoculture or xenodiagnosis in a reliable laboratory indicates true infection, but the techniques are laborious, their sensitivity in the chronic phase is generally less than 50 percent, and final results may not be available for 1 to 2 months [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/23\" class=\"abstract_t\">23</a>]. Xenodiagnosis consists of feeding laboratory-reared uninfected triatomine bugs directly on the patient or on blood in a membrane-feeding device.</p><p>The United States Centers for Disease Control and Prevention (CDC) provides consultation to healthcare providers concerning Chagas disease diagnostic testing and acts as a reference laboratory for Chagas disease serology and PCR (Division of Parasitic Diseases Public Inquiries line, 404-718-4745; for emergencies after business hours, 770-488-7100; email parasites@cdc.gov).</p><p>Issues related to monitoring after transplantation in a patient with chronic <em>T. cruzi</em> infection are discussed separately. (See <a href=\"topic.htm?path=chagas-disease-in-the-immunosuppressed-host\" class=\"medical medical_review\">&quot;Chagas disease in the immunosuppressed host&quot;</a>.)</p><p>The differential diagnosis of chronic Chagas disease, including cardiomyopathy and gastrointestinal disease, is reviewed separately. (See <a href=\"topic.htm?path=chagas-heart-disease-clinical-manifestations-and-diagnosis#H755502\" class=\"medical medical_review\">&quot;Chagas heart disease: Clinical manifestations and diagnosis&quot;, section on 'Differential diagnosis'</a> and <a href=\"topic.htm?path=chagas-gastrointestinal-disease#H13928261\" class=\"medical medical_review\">&quot;Chagas gastrointestinal disease&quot;, section on 'Differential diagnosis'</a>.)</p><p class=\"headingAnchor\" id=\"H708763391\"><span class=\"h2\">Subsequent evaluation</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>After the diagnosis of chronic <em>T. cruzi</em> infection is confirmed by serologic testing, the initial evaluation consists of medical history, including a thorough review of systems with an emphasis on symptoms suggestive of cardiac arrhythmia, early congestive heart failure, thromboembolism, and gastrointestinal disease [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/3,24,25\" class=\"abstract_t\">3,24,25</a>]. Social history should include details related to potential exposure to the parasite in endemic areas or via blood transfusion or other routes. Clinical evaluation should include complete physical examination and resting 12-lead electrocardiogram (ECG) with a 30-second lead II rhythm strip [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/1,3,26\" class=\"abstract_t\">1,3,26</a>].</p><p>Further evaluation should be based on clinical findings:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with symptoms or ECG changes consistent with Chagas cardiomyopathy should undergo a comprehensive cardiac evaluation [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/3\" class=\"abstract_t\">3</a>]. Asymptomatic patients with nonspecific ECG findings should have determination of need for further evaluation assessed on an individual basis by the treating clinician. Echocardiography is warranted only in the setting of ECG abnormalities or symptoms suggestive of Chagas cardiomyopathy [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"topic.htm?path=chagas-heart-disease-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Chagas heart disease: Clinical manifestations and diagnosis&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Patients with symptoms consistent with gastrointestinal Chagas disease should undergo barium studies and other evaluation as indicated; such testing is not warranted in the absence of symptoms [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"topic.htm?path=chagas-gastrointestinal-disease\" class=\"medical medical_review\">&quot;Chagas gastrointestinal disease&quot;</a>.)</p><p/><p>Infected individuals should be counseled not to donate blood. Diagnostic screening should be offered for family members with a similar history of potential exposure to the parasite in endemic settings and all children of infected women [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/3\" class=\"abstract_t\">3</a>]. (See <a href=\"topic.htm?path=blood-donor-screening-medical-history#H13\" class=\"medical medical_review\">&quot;Blood donor screening: Medical history&quot;, section on 'Chagas disease'</a>.)</p><p class=\"headingAnchor\" id=\"H1718466440\"><span class=\"h1\">TREATMENT</span></p><p class=\"headingAnchor\" id=\"H745613471\"><span class=\"h2\">Clinical approach</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The approach to antitrypanosomal therapy for Chagas disease varies by phase and form of disease (<a href=\"image.htm?imageKey=ID%2F65745\" class=\"graphic graphic_table graphicRef65745 \">table 1</a>). Antitrypansomal drugs include <a href=\"topic.htm?path=benznidazole-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">benznidazole</a> and nifurtimox; in general, benznidazole is better tolerated so is favored as the first-line treatment for Chagas disease. Dosing and adverse effects are outlined in the tables (<a href=\"image.htm?imageKey=ID%2F54443\" class=\"graphic graphic_table graphicRef54443 \">table 2</a> and <a href=\"image.htm?imageKey=ID%2F67193\" class=\"graphic graphic_table graphicRef67193 \">table 3</a>). Issues related to antitrypanosomal drugs are discussed further separately. (See <a href=\"topic.htm?path=chagas-disease-antitrypanosomal-drug-therapy\" class=\"medical medical_review\">&quot;Chagas disease: Antitrypanosomal drug therapy&quot;</a>.)</p><p>Antitrypanosomal treatment is warranted in children 18 years or younger with chronic <em>T. cruzi</em> infection. The evidence for this approach comes from two randomized double-blinded, placebo-controlled trials conducted in the 1990s among children 6 to 12 years old with asymptomatic chronic <em>T. cruzi</em> infection [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/27,28\" class=\"abstract_t\">27,28</a>]. The efficacy of <a href=\"topic.htm?path=benznidazole-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">benznidazole</a> over placebo was about 60 percent, as demonstrated by conversion from seropositive to seronegative three to four years after the end of treatment. However, these trials each used a different experimental serologic assay, neither of which is performed in routine diagnostic laboratories. In one of these studies, 90 percent of treated children remained positive by conventional serological tests four years after treatment, though generally with lower titers of antibodies [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/28\" class=\"abstract_t\">28</a>]. In the same trial, treated children also had a 90 percent reduction in positive xenodiagnoses compared with the placebo group [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/28\" class=\"abstract_t\">28</a>]. Benznidazole is well tolerated in children [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/28,29\" class=\"abstract_t\">28,29</a>].</p><p>Few rigorous clinical trials of antitrypanosomal therapy in adults with chronic <em>T. cruzi</em> infection have been conducted [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/30-32\" class=\"abstract_t\">30-32</a>]. A major barrier to such trials is the lack of a true test of cure and the fact that reversion to negative serology in cured patients takes many decades in those treated as adults [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/13,33,34\" class=\"abstract_t\">13,33,34</a>] (see <a href=\"#H2413657394\" class=\"local\">'Assessing response to treatment'</a> below). The evidence base for adult treatment is therefore weaker than for treatment of children [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/3\" class=\"abstract_t\">3</a>]. Nevertheless, clinical trials confirm that 85 to 95 percent of adult patients who complete a course of <a href=\"topic.htm?path=benznidazole-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">benznidazole</a> have sustained parasitological response at 12 months post-treatment based on rigorously standardized quantitative PCR assays [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/35,36\" class=\"abstract_t\">35,36</a>].</p><p>Antitrypanosomal treatment is warranted for adults with the indeterminate form of chronic <em>T. cruzi</em> infection (positive serology but no signs or symptoms of Chagas cardiomyopathy or gastrointestinal disease). Antitrypanosomal treatment does not benefit patients with established cardiomyopathy [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/36\" class=\"abstract_t\">36</a>]. Clinical trial data are inadequate to assess the likelihood of benefit for adults with very early signs of cardiomyopathy (eg, electrocardiogram changes in the absence of congestive heart failure); many experts favor treatment for this group based on observational data that suggest that treatment may slow cardiac progression [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/3,4,37,38\" class=\"abstract_t\">3,4,37,38</a>]. Issues related to antitrypanosomal therapy in patients with Chagas cardiomyopathy are discussed further separately. (See <a href=\"topic.htm?path=chagas-heart-disease-treatment-and-prognosis#H372251508\" class=\"medical medical_review\">&quot;Chagas heart disease: Treatment and prognosis&quot;, section on 'Management'</a>.)</p><p>Antitrypanosomal therapy should be considered on an individual basis for individuals older than 50 years, since the risk of drug toxicity may be higher than in younger adults [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/3,39\" class=\"abstract_t\">3,39</a>]. Stronger consideration of treatment may be warranted for women of reproductive age since observational data strongly suggest that drug treatment reduces the probability of congenital transmission [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/34,40\" class=\"abstract_t\">34,40</a>].</p><p>Antitrypanosomal therapy is not warranted for patients with advanced Chagas cardiac disease, as the available drugs are not effective for reversal of existing pathology [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/41\" class=\"abstract_t\">41</a>]. In such patients, the focus of management is supportive care for heart failure, arrhythmia, and thromboembolism [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/2,42\" class=\"abstract_t\">2,42</a>]. (See <a href=\"topic.htm?path=chagas-heart-disease-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">&quot;Chagas heart disease: Clinical manifestations and diagnosis&quot;</a>.)</p><p>Among patients with gastrointestinal Chagas disease, there are no data to suggest that antitrypanosomal therapy alters the course of illness; management focuses on symptom amelioration [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/43\" class=\"abstract_t\">43</a>]. The choice of antitrypanosomal therapy in these patients should be based on the likelihood of reducing risk of development or progression of heart disease. The factors outlined above, including age and possibility of congenital transmission, are relevant considerations. Drug absorption may be impaired in patients with megaesophagus; treatment should be delayed until after corrective surgical intervention. (See <a href=\"topic.htm?path=chagas-gastrointestinal-disease\" class=\"medical medical_review\">&quot;Chagas gastrointestinal disease&quot;</a>.)</p><p>Antitrypanosomal agents are contraindicated in pregnancy and in patients with severe renal or hepatic dysfunction.</p><p class=\"headingAnchor\" id=\"H2413657394\"><span class=\"h2\">Assessing response to treatment</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There is no sensitive, timely assay for monitoring response to treatment in patients with chronic <em>T. cruzi</em> infection [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/3\" class=\"abstract_t\">3</a>]. The length of time required for serologic test results to become negative following treatment is proportional to the duration of infection; because most individuals who grew up in an area with endemic vector-borne transmission become infected as children, patient age is often used a proxy for the presumed duration of infection. As an example, among females treated by age 15 years, the median time to negative serology in one study was 15 years, whereas among women treated after age 15 years, the median time to negative serology was 27 years [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/34\" class=\"abstract_t\">34</a>]. The two randomized placebo-controlled trials of <a href=\"topic.htm?path=benznidazole-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">benznidazole</a> in children used experimental assays measuring lytic antibodies to demonstrate response at three to four years post-treatment, but these assays are not available outside a few research settings [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/27,28\" class=\"abstract_t\">27,28</a>]. There is thus no practical method to prove treatment success in the chronic phase, and serological monitoring post-treatment is not recommended for those treated in the chronic phase [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/3\" class=\"abstract_t\">3</a>].</p><p>In trials of <a href=\"topic.htm?path=posaconazole-drug-information\" class=\"drug drug_general\">posaconazole</a> and the ravuconazole pro-drug E1224, the main outcome was parasite detection by carefully standardized real-time polymerase chain reaction (PCR) in multiple specimens [<a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/44-46\" class=\"abstract_t\">44-46</a>]. Positive PCR results during post-treatment follow-up provided an early indicator of treatment failure for the experimental arms in these trials. However, negative PCR does not provide proof of cure, and molecular methods are not appropriate for routine clinical use to monitor response to treatment in patients with chronic <em>T. cruzi</em> infection.</p><p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\"><span class=\"h1\">INFORMATION FOR PATIENTS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>UpToDate offers two types of patient education materials, &quot;The Basics&quot; and &quot;Beyond the Basics.&quot; The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &quot;patient info&quot; and the keyword(s) of interest.)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Basics topic (see <a href=\"topic.htm?path=chagas-disease-the-basics\" class=\"medical medical_basics\">&quot;Patient education: Chagas disease (The Basics)&quot;</a>)</p><p/><p class=\"headingAnchor\" id=\"H1285149509\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><em>Trypanosoma cruzi</em> infection is characterized by two phases, acute and chronic. The acute phase of <em>T. cruzi</em> infection lasts 8 to 12 weeks following transmission and is characterized by presence of circulating trypomastigotes. When the host immune response succeeds in decreasing parasite replication, parasitemia falls below levels detectable by microscopy, acute symptoms resolve, and the patient passes into the chronic phase, which lasts for the life of the patient. (See <a href=\"#H481275196\" class=\"local\">'Natural history'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Nearly all <em>T. cruzi&ndash;</em>infected persons have the indeterminate (asymptomatic) form during the first one to three decades of the chronic phase. Patients with the indeterminate form of the chronic phase of <em>T. cruzi</em> infection have positive serology but no signs or symptoms of cardiomyopathy or gastrointestinal disease. Such patients have normal 12-lead electrocardiogram findings and normal radiographic examinations of the chest, esophagus, and colon. An estimated 20 to 30 percent subsequently develop clinically evident cardiac <span class=\"nowrap\">and/or</span> gastrointestinal forms of the disease. (See <a href=\"#H771514762\" class=\"local\">'Indeterminate form'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Chronic Chagas disease should be suspected in individuals who have lived in endemic countries of Latin America and those born to women from endemic countries, especially including those who lived in rural areas in houses with adobe walls, thatched roofs, <span class=\"nowrap\">and/or</span> known triatomine infestation. Most infected individuals are asymptomatic; cardiac or gastrointestinal symptoms in a patient from Latin America should prompt consideration of chronic Chagas disease. Vector-borne transmission also occurs in the southern United States, but the risk is much lower than in areas of Latin America with domestic triatomine infestation. (See <a href=\"#H1462222214\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Diagnosis of chronic infection requires serological methods to detect immunoglobulin (Ig)G antibodies to <em>T. cruzi</em>. Two tests based on different antigens <span class=\"nowrap\">and/or</span> techniques are used in parallel to increase the accuracy of the diagnosis; no available assay has sufficient sensitivity and specificity to be used alone. (See <a href=\"#H3676202985\" class=\"local\">'Laboratory testing'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>After the diagnosis of chronic <em>T. cruzi</em> infection is confirmed by serologic testing, the initial evaluation consists of medical history, including a thorough review of systems with an emphasis on symptoms suggestive of cardiac arrhythmia, early congestive heart failure, thromboembolism, and gastrointestinal disease. Social history should include details related to potential exposure to the parasite in endemic areas or via blood transfusion or other routes. Clinical evaluation should include complete physical examination and resting 12-lead electrocardiogram (ECG) with a 30-second lead II rhythm strip. (See <a href=\"#H708763391\" class=\"local\">'Subsequent evaluation'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The approach to antitrypanosomal therapy for Chagas disease varies by phase and form of disease (<a href=\"image.htm?imageKey=ID%2F65745\" class=\"graphic graphic_table graphicRef65745 \">table 1</a>). Antitrypansomal drugs include <a href=\"topic.htm?path=benznidazole-united-states-available-via-cdc-drug-service-investigational-drug-ind-protocol-only-drug-information\" class=\"drug drug_general\">benznidazole</a> and nifurtimox; in general, benznidazole is better tolerated so is favored as the first-line treatment for Chagas disease. Dosing and adverse effects are outlined in the tables (<a href=\"image.htm?imageKey=ID%2F54443\" class=\"graphic graphic_table graphicRef54443 \">table 2</a> and <a href=\"image.htm?imageKey=ID%2F67193\" class=\"graphic graphic_table graphicRef67193 \">table 3</a>). Issues related to antitrypanosomal drugs are discussed further separately. (See <a href=\"#H745613471\" class=\"local\">'Clinical approach'</a> above and <a href=\"topic.htm?path=chagas-disease-antitrypanosomal-drug-therapy\" class=\"medical medical_review\">&quot;Chagas disease: Antitrypanosomal drug therapy&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We recommend antitrypanosomal therapy in the setting of chronic infection among patients &le;18 years of age [(<a href=\"grade.htm?i=1\" class=\"grade\">Grade 1A</a>) for patients &le;12 years; (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>) for patients 13 to 18 years]. We also recommend antitrypanosomal therapy in the setting of reactivated infection (<a href=\"grade.htm?i=2\" class=\"grade\">Grade 1B</a>). We suggest antitrypanosomal therapy for individuals between 19 and 50 years of age without established Chagas cardiomyopathy (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Antitrypanosomal therapy should be considered on an individual basis for individuals older than 50 years, since the risk of drug toxicity may be higher than in younger adults. (See <a href=\"#H745613471\" class=\"local\">'Clinical approach'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest NOT administering antitrypanosomal therapy for patients with established Chagas cardiomyopathy (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). This is discussed further separately. (See <a href=\"topic.htm?path=chagas-heart-disease-treatment-and-prognosis#H372251508\" class=\"medical medical_review\">&quot;Chagas heart disease: Treatment and prognosis&quot;, section on 'Management'</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest NOT administering antitrypanosomal therapy for patients with Chagas gastrointestinal disease (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). This is discussed further separately. (See <a href=\"topic.htm?path=chagas-gastrointestinal-disease\" class=\"medical medical_review\">&quot;Chagas gastrointestinal disease&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>We suggest NOT administering preemptive antitrypanosomal therapy for patients at risk of reactivation (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). This is discussed further separately. (See <a href=\"topic.htm?path=chagas-disease-in-the-immunosuppressed-host\" class=\"medical medical_review\">&quot;Chagas disease in the immunosuppressed host&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Thus far, there is no practical method to assess response to treatment in the chronic phase; serological monitoring post-treatment is not useful. (See <a href=\"#H2413657394\" class=\"local\">'Assessing response to treatment'</a> above.)</p><p/></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/1\" class=\"nounderline abstract_t\">Bern C. Chagas' Disease. N Engl J Med 2015; 373:456.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/2\" class=\"nounderline abstract_t\">Rassi A Jr, Rassi A, Marin-Neto JA. Chagas disease. Lancet 2010; 375:1388.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/3\" class=\"nounderline abstract_t\">Bern C, Montgomery SP, Herwaldt BL, et al. Evaluation and treatment of chagas disease in the United States: a systematic review. JAMA 2007; 298:2171.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/4\" class=\"nounderline abstract_t\">Dias JC, Ramos AN Jr, Gontijo ED, et al. [Brazilian Consensus on Chagas Disease, 2015]. Epidemiol Serv Saude 2016; 25:7.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/5\" class=\"nounderline abstract_t\">Marin-Neto JA, Bromberg-Marin G, Pazin-Filho A, et al. Cardiac autonomic impairment and early myocardial damage involving the right ventricle are independent phenomena in Chagas' disease. Int J Cardiol 1998; 65:261.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/6\" class=\"nounderline abstract_t\">Genovese O, Ballario C, Storino R, et al. Clinical manifestations of peripheral nervous system involvement in human chronic Chagas disease. Arq Neuropsiquiatr 1996; 54:190.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/7\" class=\"nounderline abstract_t\">Bern C. Chagas disease in the immunosuppressed host. Curr Opin Infect Dis 2012; 25:450.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/8\" class=\"nounderline abstract_t\">Martinez-Perez A, Norman FF, Monge-Maillo B, et al. An approach to the management of Trypanosoma cruzi infection (Chagas' disease) in immunocompromised patients. Expert Rev Anti Infect Ther 2014; 12:357.</a></li><li class=\"breakAll\">World Health Organization. Control of Chagas Disease: Second report of the WHO expert committee. WHO, Geneva 2002. http://apps.who.int/iris/bitstream/10665/42443/1/WHO_TRS_905.pdf (Accessed on August 01, 2017).</li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/10\" class=\"nounderline abstract_t\">Sosa-Estani S, Gamboa-Le&oacute;n MR, Del Cid-Lemus J, et al. Use of a rapid test on umbilical cord blood to screen for Trypanosoma cruzi infection in pregnant women in Argentina, Bolivia, Honduras, and Mexico. Am J Trop Med Hyg 2008; 79:755.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/11\" class=\"nounderline abstract_t\">Umezawa ES, Bastos SF, Camargo ME, et al. Evaluation of recombinant antigens for serodiagnosis of Chagas' disease in South and Central America. J Clin Microbiol 1999; 37:1554.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/12\" class=\"nounderline abstract_t\">Verani JR, Seitz A, Gilman RH, et al. Geographic variation in the sensitivity of recombinant antigen-based rapid tests for chronic Trypanosoma cruzi infection. Am J Trop Med Hyg 2009; 80:410.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/13\" class=\"nounderline abstract_t\">Tarleton RL, Reithinger R, Urbina JA, et al. The challenges of Chagas Disease-- grim outlook or glimmer of hope. PLoS Med 2007; 4:e332.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/14\" class=\"nounderline abstract_t\">Leiby DA, Wendel S, Takaoka DT, et al. Serologic testing for Trypanosoma cruzi: comparison of radioimmunoprecipitation assay with commercially available indirect immunofluorescence assay, indirect hemagglutination assay, and enzyme-linked immunosorbent assay kits. J Clin Microbiol 2000; 38:639.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/15\" class=\"nounderline abstract_t\">Silveira-Lacerda EP, Silva AG, Junior SF, et al. Chagas' disease: application of TESA-blot in inconclusive sera from a Brazilian blood bank. Vox Sang 2004; 87:204.</a></li><li class=\"breakAll\">Lopez-Velez R, Norman FF, Bern C. American Trypanosomiasis (Chagas Disease). In: Hunter's Tropical Medicine and Emerging Infectious Desease, 9th ed, Magill AJ, Ryan ET, Solomon T, Hill DR (Eds), Saunders, Philadelphia 2013. p.725.</li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/17\" class=\"nounderline abstract_t\">Gorlin J, Rossmann S, Robertson G, et al. Evaluation of a new Trypanosoma cruzi antibody assay for blood donor screening. Transfusion 2008; 48:531.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/18\" class=\"nounderline abstract_t\">Ram&iacute;rez JD, Guhl F, Umezawa ES, et al. Evaluation of adult chronic Chagas' heart disease diagnosis by molecular and serological methods. J Clin Microbiol 2009; 47:3945.</a></li><li class=\"breakAll\">InBios. FDA Clears First Point of Care Rapid Diagnostic Test Kit for Chagas Disease. Seattle, 2016. http://www.prweb.com/releases/2016/12/prweb13938661.htm (Accessed on August 01, 2017).</li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/20\" class=\"nounderline abstract_t\">Shah V, Ferrufino L, Gilman RH, et al. Field evaluation of the InBios Chagas detect plus rapid test in serum and whole-blood specimens in Bolivia. Clin Vaccine Immunol 2014; 21:1645.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/21\" class=\"nounderline abstract_t\">Schijman AG, Bisio M, Orellana L, et al. International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients. PLoS Negl Trop Dis 2011; 5:e931.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/22\" class=\"nounderline abstract_t\">Qvarnstrom Y, Schijman AG, Veron V, et al. Sensitive and specific detection of Trypanosoma cruzi DNA in clinical specimens using a multi-target real-time PCR approach. PLoS Negl Trop Dis 2012; 6:e1689.</a></li><li class=\"breakAll\">Williams JE. Leishmania and Trypanosoma. In: Medical Parasitology: A Practical Approach, Gillespie SH, Hawkey PM (Eds), Oxford University Press, Oxford, UK 1995. p.151.</li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/24\" class=\"nounderline abstract_t\">Bern C. Antitrypanosomal therapy for chronic Chagas' disease. N Engl J Med 2011; 364:2527.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/25\" class=\"nounderline abstract_t\">P&eacute;rez-Molina JA, Molina I. Chagas disease. Lancet 2018; 391:82.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/26\" class=\"nounderline abstract_t\">L&aacute;zzari JO, Pereira M, Antunes CM, et al. Diagnostic electrocardiography in epidemiological studies of Chagas' disease: multicenter evaluation of a standardized method. Rev Panam Salud Publica 1998; 4:317.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/27\" class=\"nounderline abstract_t\">de Andrade AL, Zicker F, de Oliveira RM, et al. Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection. Lancet 1996; 348:1407.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/28\" class=\"nounderline abstract_t\">Sosa Estani S, Segura EL, Ruiz AM, et al. Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease. Am J Trop Med Hyg 1998; 59:526.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/29\" class=\"nounderline abstract_t\">Altcheh J, Moscatelli G, Moroni S, et al. Adverse events after the use of benznidazole in infants and children with Chagas disease. Pediatrics 2011; 127:e212.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/30\" class=\"nounderline abstract_t\">P&eacute;rez-Molina JA, P&eacute;rez-Ayala A, Moreno S, et al. Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis. J Antimicrob Chemother 2009; 64:1139.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/31\" class=\"nounderline abstract_t\">Reyes PA, Vallejo M. Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection). Cochrane Database Syst Rev 2005; :CD004102.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/32\" class=\"nounderline abstract_t\">Villar JC, Perez JG, Cortes OL, et al. Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. Cochrane Database Syst Rev 2014; :CD003463.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/33\" class=\"nounderline abstract_t\">Pinazo MJ, Thomas MC, Bua J, et al. Biological markers for evaluating therapeutic efficacy in Chagas disease, a systematic review. Expert Rev Anti Infect Ther 2014; 12:479.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/34\" class=\"nounderline abstract_t\">Fabbro DL, Danesi E, Olivera V, et al. Trypanocide treatment of women infected with Trypanosoma cruzi and its effect on preventing congenital Chagas. PLoS Negl Trop Dis 2014; 8:e3312.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/35\" class=\"nounderline abstract_t\">Molina I, G&oacute;mez i Prat J, Salvador F, et al. Randomized trial of posaconazole and benznidazole for chronic Chagas' disease. N Engl J Med 2014; 370:1899.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/36\" class=\"nounderline abstract_t\">Morillo CA, Waskin H, Sosa-Estani S, et al. Benznidazole and Posaconazole in&nbsp;Eliminating Parasites in Asymptomatic&nbsp;T.&nbsp;Cruzi Carriers: The STOP-CHAGAS Trial. J Am Coll Cardiol 2017; 69:939.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/37\" class=\"nounderline abstract_t\">Viotti R, Vigliano C, Lococo B, et al. Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial. Ann Intern Med 2006; 144:724.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/38\" class=\"nounderline abstract_t\">Rassi A Jr, Marin JA Neto, Rassi A. Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of aetiological treatment following the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial. Mem Inst Oswaldo Cruz 2017; 112:224.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/39\" class=\"nounderline abstract_t\">Wegner DH, Rohwedder RW. Experience with nifurtimox in chronic Chagas' infection. Preliminary report. Arzneimittelforschung 1972; 22:1635.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/40\" class=\"nounderline abstract_t\">Murcia L, Sim&oacute;n M, Carrilero B, et al. Treatment of Infected Women of Childbearing Age Prevents Congenital Trypanosoma cruzi Infection by Eliminating the Parasitemia Detected by PCR. J Infect Dis 2017; 215:1452.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/41\" class=\"nounderline abstract_t\">Morillo CA, Marin-Neto JA, Avezum A, et al. Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. N Engl J Med 2015; 373:1295.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/42\" class=\"nounderline abstract_t\">Rassi A Jr, Rassi A, Little WC. Chagas' heart disease. Clin Cardiol 2000; 23:883.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/43\" class=\"nounderline abstract_t\">de Oliveira RB, Troncon LE, Dantas RO, Menghelli UG. Gastrointestinal manifestations of Chagas' disease. Am J Gastroenterol 1998; 93:884.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/44\" class=\"nounderline abstract_t\">Molina I, Salvador F, S&aacute;nchez-Montalv&aacute; A. Posaconazole versus benznidazole for chronic Chagas' disease. N Engl J Med 2014; 371:966.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/45\" class=\"nounderline abstract_t\">Ram&iacute;rez JC, Cura CI, da Cruz Moreira O, et al. Analytical Validation of Quantitative Real-Time PCR Methods for Quantification of Trypanosoma cruzi DNA in Blood Samples from Chagas Disease Patients. J Mol Diagn 2015; 17:605.</a></li><li><a href=\"https://www.uptodate.com/contents/chagas-disease-chronic-trypanosoma-cruzi-infection/abstract/46\" class=\"nounderline abstract_t\">Chatelain E. Chagas disease drug discovery: toward a new era. J Biomol Screen 2015; 20:22.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 114192 Version 2.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H1285149509\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H707610184\" id=\"outline-link-H707610184\">INTRODUCTION</a></li><li><a href=\"#H481275196\" id=\"outline-link-H481275196\">NATURAL HISTORY</a><ul><li><a href=\"#H2906167089\" id=\"outline-link-H2906167089\">Overview</a></li><li><a href=\"#H771514762\" id=\"outline-link-H771514762\">Indeterminate form</a></li><li><a href=\"#H2096355592\" id=\"outline-link-H2096355592\">Determinate forms</a><ul><li><a href=\"#H960078338\" id=\"outline-link-H960078338\">- Heart disease</a></li><li><a href=\"#H1975704446\" id=\"outline-link-H1975704446\">- Gastrointestinal disease</a></li></ul></li><li><a href=\"#H3679823478\" id=\"outline-link-H3679823478\">Reactivation due to immunosuppression</a></li></ul></li><li><a href=\"#H1462222214\" id=\"outline-link-H1462222214\">DIAGNOSIS</a><ul><li><a href=\"#H3676202985\" id=\"outline-link-H3676202985\">Laboratory testing</a></li><li><a href=\"#H708763391\" id=\"outline-link-H708763391\">Subsequent evaluation</a></li></ul></li><li><a href=\"#H1718466440\" id=\"outline-link-H1718466440\">TREATMENT</a><ul><li><a href=\"#H745613471\" id=\"outline-link-H745613471\">Clinical approach</a></li><li><a href=\"#H2413657394\" id=\"outline-link-H2413657394\">Assessing response to treatment</a></li></ul></li><li><a href=\"#PATIENT_INFORMATION\" id=\"outline-link-H724873096\">INFORMATION FOR PATIENTS</a></li><li><a href=\"#H1285149509\" id=\"outline-link-H1285149509\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"ID/114192|FIG\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"FIGURES\">FIGURES</a></div><ul><li><a href=\"image.htm?imageKey=ID/114565\" class=\"graphic graphic_figure\">- Natural history of Chagas disease</a></li></ul></li><li><div id=\"ID/114192|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=ID/65745\" class=\"graphic graphic_table\">- Treatment of Chagas disease</a></li><li><a href=\"image.htm?imageKey=ID/54443\" class=\"graphic graphic_table\">- Antitrypanosomal drugs dosing</a></li><li><a href=\"image.htm?imageKey=ID/67193\" class=\"graphic graphic_table\">- Side effects of antitrypanosomal drugs</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=blood-donor-screening-medical-history\" class=\"medical medical_review\">Blood donor screening: Medical history</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chagas-disease-in-the-immunosuppressed-host\" class=\"medical medical_review\">Chagas disease in the immunosuppressed host</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chagas-disease-acute-and-congenital-trypanosoma-cruzi-infection\" class=\"medical medical_review\">Chagas disease: Acute and congenital Trypanosoma cruzi infection</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chagas-disease-antitrypanosomal-drug-therapy\" class=\"medical medical_review\">Chagas disease: Antitrypanosomal drug therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chagas-disease-epidemiology-and-prevention\" class=\"medical medical_review\">Chagas disease: Epidemiology and prevention</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chagas-gastrointestinal-disease\" class=\"medical medical_review\">Chagas gastrointestinal disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chagas-heart-disease-clinical-manifestations-and-diagnosis\" class=\"medical medical_review\">Chagas heart disease: Clinical manifestations and diagnosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chagas-heart-disease-treatment-and-prognosis\" class=\"medical medical_review\">Chagas heart disease: Treatment and prognosis</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=chagas-disease-the-basics\" class=\"medical medical_basics\">Patient education: Chagas disease (The Basics)</a></li></ul></div></div>","javascript":null}